Who Paid My Doc
Clair Francomano
Clinical Molecular Genetics Indianapolis, IN Medical Doctor
NPI 1083657613 CMS profile 679102
1002 Wishard Blvd, Indianapolis, IN 46202
General payments
$2,303
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Clair Francomano of Indianapolis, IN is reported in the CMS Open Payments database as having received $2,303 across 4 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,168 | 2 | |
| 2023 | General | $122 | 1 | |
| 2019 | General | $13 | 1 |
Beside peers
- Clair Francomano
- Indiana median
- Middle half of Indiana
- National median
In program year 2025, general payments to Clair Francomano were reported at $2,168. Among 20,565 Indiana profiles paid that year, the median was $180 and the middle half received between $52 and $617.
Show as a table
| Year | Clair Francomano | Indiana median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $13 | $168 | $50–$632 | $163 |
| 2020 | $0 | $107 | $35–$375 | $114 |
| 2021 | $0 | $137 | $39–$503 | $132 |
| 2022 | $0 | $151 | $44–$537 | $149 |
| 2023 | $122 | $166 | $49–$580 | $160 |
| 2024 | $0 | $180 | $50–$625 | $164 |
| 2025 | $2,168 | $180 | $52–$617 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
29
Drug cost
$8,648
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Cromolyn Sodium | Generic | 29 | $8,648 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.
Billing to Medicare
Part B · data year 2024 · 4 billing codesPaid by Medicare
$4,224
Medicare patients
24
Services billed
71
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 67% | |
| High blood pressure | 50% | |
| Depression | 50% | |
| Heart failure | 0% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
4 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Molecular Genetics in Indiana
Related records
Clinical Molecular Genetics in Indiana
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Molecular Genetics
Everyone recorded under this specialty, nationwide.
Doctors in Indiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.